Universal Ibogaine Inc.
IBOGF
$0.065
-$0.005-7.14%
| Weiss Ratings | IBOGF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | IBOGF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | IBOGF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -4.53 | |||
| Price History | IBOGF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 98.17% | |||
| 30-Day Total Return | 185.09% | |||
| 60-Day Total Return | 316.67% | |||
| 90-Day Total Return | 755.26% | |||
| Year to Date Total Return | 333.33% | |||
| 1-Year Total Return | 247.59% | |||
| 2-Year Total Return | 339.19% | |||
| 3-Year Total Return | -7.14% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -30.00% | |||
| 52-Week Low % Change | 5,284.62% | |||
| Price | IBOGF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.10 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Aug 21, 2024 | |||
| 52-Week High Price (Date) | Mar 05, 2025 | |||
| Valuation | IBOGF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 5.35M | |||
| Enterprise Value | 6.95M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.01 | |||
| Earnings Per Share Growth | -81.41% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 11.67 | |||
| Price/Book (Q) | 17.95 | |||
| Enterprise Value/Revenue (TTM) | 4.02 | |||
| Price | $0.07 | |||
| Enterprise Value/EBITDA (TTM) | -19.66 | |||
| Enterprise Value/EBIT | -11.57 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | IBOGF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 284.45M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | IBOGF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 855-426-4246 | |||
| Address | 815 8th Avenue SW Calgary, AB T2P 3P2 | |||
| Website | universalibogaine.com | |||
| Country | Canada | |||
| Year Founded | -- | |||
| Profitability | IBOGF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -34.76% | |||
| Profit Margin | -66.82% | |||
| Management Effectiveness | IBOGF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -9.16% | |||
| Return on Equity | -- | |||
| Income Statement | IBOGF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.73M | |||
| Total Revenue (TTM) | 1.73M | |||
| Revenue Per Share | $0.01 | |||
| Gross Profit (TTM) | 489.40K | |||
| EBITDA (TTM) | -353.40K | |||
| EBIT (TTM) | -600.80K | |||
| Net Income (TTM) | -1.15M | |||
| Net Income Avl. to Common (TTM) | -1.15M | |||
| Total Revenue Growth (Q YOY) | 25.08% | |||
| Earnings Growth (Q YOY) | -76.87% | |||
| EPS Diluted (TTM) | -0.01 | |||
| EPS Diluted Growth (Q YOY) | -15.79% | |||
| Balance Sheet | IBOGF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 342.10K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 529.60K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.13M | |||
| Current Ratio (Q) | 0.648 | |||
| Book Value Per Share (Q) | $0.00 | |||
| Total Assets (Q) | 3.87M | |||
| Total Current Liabilities (Q) | 817.20K | |||
| Total Debt (Q) | 2.02M | |||
| Total Liabilities (Q) | 2.74M | |||
| Total Common Equity (Q) | 1.13M | |||
| Cash Flow | IBOGF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -15.90K | |||
| Cash from Financing (TTM) | 653.80K | |||
| Net Change in Cash (TTM) | 86.70K | |||
| Levered Free Cash Flow (TTM) | -238.40K | |||
| Cash from Operations (TTM) | -551.30K | |||
